JP2024514352A - グルカゴン様ペプチド化合物 - Google Patents

グルカゴン様ペプチド化合物 Download PDF

Info

Publication number
JP2024514352A
JP2024514352A JP2023564257A JP2023564257A JP2024514352A JP 2024514352 A JP2024514352 A JP 2024514352A JP 2023564257 A JP2023564257 A JP 2023564257A JP 2023564257 A JP2023564257 A JP 2023564257A JP 2024514352 A JP2024514352 A JP 2024514352A
Authority
JP
Japan
Prior art keywords
compound
formula
acceptable salt
mmol
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514352A5 (https=
Inventor
ボーリュー，バレリー
ガルヤン，キース
ガオ，ジンハイ
ギンスバーグ‐モラフ，キャロル
ジェイン，パンカジュ
マルチンケビシエン，ジョビタ
マイケル，ウォルター
宗人 茂木
マロ，マーティン
パテル，セジャル
プルマー，スコット
シン，アロック
ウセラ，エイミー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024514352A publication Critical patent/JP2024514352A/ja
Publication of JP2024514352A5 publication Critical patent/JP2024514352A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023564257A 2021-04-21 2022-04-20 グルカゴン様ペプチド化合物 Pending JP2024514352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21169757 2021-04-21
EP21169757.8 2021-04-21
PCT/IB2022/053698 WO2022224164A1 (en) 2021-04-21 2022-04-20 Glucagon like peptide compounds

Publications (2)

Publication Number Publication Date
JP2024514352A true JP2024514352A (ja) 2024-04-01
JP2024514352A5 JP2024514352A5 (https=) 2025-04-15

Family

ID=75639721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564257A Pending JP2024514352A (ja) 2021-04-21 2022-04-20 グルカゴン様ペプチド化合物

Country Status (14)

Country Link
US (1) US20240247042A1 (https=)
EP (1) EP4326330A1 (https=)
JP (1) JP2024514352A (https=)
KR (1) KR20230171471A (https=)
CN (1) CN117202936A (https=)
AR (1) AR125400A1 (https=)
AU (1) AU2022260805A1 (https=)
BR (1) BR112023021597A2 (https=)
CA (1) CA3216058A1 (https=)
CL (1) CL2023003091A1 (https=)
IL (1) IL307822A (https=)
MX (1) MX2023012290A (https=)
TW (1) TW202304500A (https=)
WO (1) WO2022224164A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4048664A1 (en) 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
IL306110A (en) 2021-04-21 2023-11-01 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519024A (ja) * 2014-06-23 2017-07-13 ノバルティス アーゲー 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP6730278B2 (ja) * 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
MA41580A (fr) * 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519024A (ja) * 2014-06-23 2017-07-13 ノバルティス アーゲー 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用

Also Published As

Publication number Publication date
EP4326330A1 (en) 2024-02-28
IL307822A (en) 2023-12-01
CL2023003091A1 (es) 2024-05-03
WO2022224164A1 (en) 2022-10-27
CA3216058A1 (en) 2022-10-27
TW202304500A (zh) 2023-02-01
CN117202936A (zh) 2023-12-08
AR125400A1 (es) 2023-07-12
BR112023021597A2 (pt) 2024-02-06
MX2023012290A (es) 2023-10-26
KR20230171471A (ko) 2023-12-20
US20240247042A1 (en) 2024-07-25
AU2022260805A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
TWI792596B (zh) 新穎脂肪酸及其於共軛至生物分子之用途
JP2024514352A (ja) グルカゴン様ペプチド化合物
WO2022219495A1 (en) 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
US12171836B2 (en) Long-acting adrenomedullin derivative
TW201105327A (en) Modulators of metabolism and the treatment of disorders related thereto
EP4476212A1 (en) 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
KR20210102345A (ko) 펩티드 결합제
KR20240000510A (ko) 소르틸린 활성 조절제
JP7812338B2 (ja) Ｇｌｐ受容体アゴニスト
US20240408218A1 (en) Conjugates of glucagon and ampk activators
WO2017075583A2 (en) Oxyntomodulin analogs and methods of making and using same
EP4323354B1 (en) 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2026052063A1 (en) Glp-1 polypeptide prodrugs and uses thereof
AU2021236951A1 (en) Oral GLP receptor agonists
RU2838225C1 (ru) Агонисты рецепторов glp
RU2836443C1 (ru) Пероральные агонисты рецепторов glp
CN118715220A (zh) 2-((4-((s)-2-(4-氯-2-氟苯基)-2-甲基苯并[d][1,3]二氧戊环-4-基)哌啶-1-基)甲基)-1-(((s)-氧杂环丁烷-2-基)甲基)-1h-咪唑衍生物作为glp1受体激活剂用于治疗肥胖症
WO2026082119A1 (zh) 一种多肽化合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203